Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 6/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19337256 | 0.86 | FAAH (0.42) | SLC6A4PRKDCPIK3CAFAAHTRPV1 | |
| SCHEMBL20162205 | 0.80 | MAP3K14 (0.42) | MAT2ADRD2SLC6A4MAP3K14TRPV1 | |
| SCHEMBL28113924 | 0.73 | CYP1A2 (0.38) | MAT2ADRD2SLC6A4MAP3K14CDC7 | |
| SCHEMBL20162217 | 0.69 | MEN1 (0.55) | MAT2A | |
| SCHEMBL20162212 | 0.68 | HSD17B10 (0.38) | MAP3K14TRPV1CDC7CDK2ROCK1 | |
| SCHEMBL18386902 | 0.68 | CDC7 (0.38) | TRPV1CDC7CDK2ROCK1TP53 | |
| SCHEMBL18386916 | 0.67 | RPS6KA5 (0.47) | TRPV1 | |
| SCHEMBL21980701 | 0.66 | GRM2 (0.44) | PRKDCPIK3CAMTORROCK1 | |
| SCHEMBL20357957 | 0.65 | BCL6 (0.42) | PRKDCPIK3CAMTORMAP3K14CDC7 | |
| SCHEMBL18585985 | 0.65 | MAPK14 (0.36) | CYP11B2CYP11B1TRPV1CDC7CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345900-B1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | BEBETTER MED INC (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-11267802-B2 | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | BEBETTER MED INC. (CN) | 2022-03-08 | — | — | US | disclosed |
| US-20200331891-A9 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200165227-A1 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3345900-A1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | Guangzhou Bebetter Medicine Technology Co., Ltd. (CN) | 2018-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331891-A9 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, KRAS | MAT2A 2100/4885DRD2 2575/4885SLC6A4 1683/4885 |
| US-20200165227-A1 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, KRAS | MAT2A 2100/4885DRD2 2575/4885SLC6A4 1683/4885 |
| US-11267802-B2 | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | EGFR, ERBB2, KRAS | MAT2A 2100/4885DRD2 2575/4885SLC6A4 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.